Point72 Asset Management’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.18M Buy
11,050
+4,100
+59% +$791K ﹤0.01% 2252
2025
Q4
$1.28M Buy
6,950
+200
+3% +$35.1K ﹤0.01% 2745
2025
Q3
$1.04M Hold
6,750
﹤0.01% 1685
2025
Q2
$943K Sell
6,750
-143,250
-96% -$20.1M ﹤0.01% 1580
2025
Q1
$22.1M Buy
+150,000
New +$21.7M 0.05% 425
2024
Q1
Sell
-5,250
Closed -$707K 2176
2023
Q4
$707K Hold
5,250
﹤0.01% 1501
2023
Q3
$711K Hold
5,250
﹤0.01% 1430
2023
Q2
$751K Hold
5,250
﹤0.01% 1179
2023
Q1
$729K Sell
5,250
-362,800
-99% -$48.8M ﹤0.01% 1161
2022
Q4
$49.9M Buy
368,050
+358,600
+3,795% +$45M 0.17% 155
2022
Q3
$1.04M Hold
9,450
﹤0.01% 1049
2022
Q2
$1.25M Buy
+9,450
New +$1.24M 0.01% 1026
2019
Q3
Sell
-714,050
Closed -$59M 1135
2019
Q2
$59M Buy
+714,050
New +$56M 0.31% 75
2017
Q2
Sell
-600,000
Closed -$37.4M 830
2017
Q1
$37.4M Buy
+600,000
New +$34.9M 0.21% 133
2015
Q3
Sell
-50,200
Closed -$3.2M 759
2015
Q2
$3.2M Buy
+50,200
New +$3.44M 0.02% 517
2014
Q4
Sell
-400,000
Closed -$28.6M 664
2014
Q3
$28.6M Buy
400,000
+175,000
+78% +$12.8M 0.22% 131
2014
Q2
$16.7M Buy
+225,000
New +$16.3M 0.11% 233

Other funds holding AZN

Point72 Asset Management's AZN Position: Q1 2026 in Review

Point72 Asset Management increased its AstraZeneca (AZN) stake by 33% in Q1 2026, buying an estimated $59.3M and bringing the position to 1,233,965 shares worth $243M. The position accounts for 0.31% of the portfolio, ranked #37.

Point72 Asset Management first reported a position in AZN in Q2 2014 and has held it in 36 quarters since. The position peaked at $264M in Q3 2022. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Point72 Asset Management held 1,233,965 shares of AstraZeneca worth $243M as of Q1 2026.
  • Point72 Asset Management bought 307,594 AstraZeneca shares in Q1 2026, an estimated $59.3M.
  • AstraZeneca made up 0.31% of Point72 Asset Management's portfolio in Q1 2026, its #37 holding.
  • Point72 Asset Management first reported a position in AstraZeneca in Q2 2014 and has held it in 36 quarters since.
  • Point72 Asset Management's AstraZeneca position peaked at $264M in Q3 2022.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.